$FATE
Fate Therapeutics Inc Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000095017021003066 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$17.07M	$14.23M	$7.558M
YoY Change	7.35%	88.21%	211.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.94M	$15.72M	$8.350M
YoY Change	64.27%	88.24%	31.5%
% of Gross Profit
Research & Development	$69.52M	$53.13M	$30.69M
YoY Change	78.34%	73.1%	32.29%
% of Gross Profit
Depreciation & Amortization	$2.206M	$1.519M	$780.0K
YoY Change	156.51%	94.74%	32.2%
% of Gross Profit
Operating Expenses	$86.45M	$68.85M	$39.05M
YoY Change	75.36%	76.33%	32.14%
Operating Profit		-$54.62M	-$31.49M
YoY Change		73.48%	16.11%
Interest Expense	$761.0K	$11.32M	-$27.20M
YoY Change	-103.86%	-141.6%	-5433.33%
% of Operating Profit
Other Income/Expense, Net		$11.32M	-$27.20M
YoY Change		-141.6%
Pretax Income	-$68.62M	-$43.31M	-$58.68M
YoY Change	29.21%	-26.2%	120.52%
Income Tax
% Of Pretax Income
Net Earnings	-$68.62M	-$43.31M	-$58.68M
YoY Change	29.21%	-26.2%	120.54%
Net Earnings / Revenue	-402.02%	-304.45%	-776.45%
Basic Earnings Per Share		-$0.45
Diluted Earnings Per Share	-$716.3K	-$453.9K	-$675.3K
COMMON SHARES
Basic Shares Outstanding	95.49M	95.41M
Diluted Shares Outstanding		95.41M

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$615.9M	$678.7M	$488.8M
YoY Change	27.54%	38.85%	61.43%
Cash & Equivalents	$133.6M	$129.2M	$349.1M
Short-Term Investments	$482.3M	$549.5M	$139.7M
Other Short-Term Assets	$8.826M	$7.701M	$4.700M
YoY Change	49.59%	63.85%	67.86%
Inventory
Prepaid Expenses
Receivables	$8.676M	$7.311M	$3.200M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$633.4M	$693.7M	$496.8M
YoY Change	28.14%	39.64%	62.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$91.53M	$74.62M	$87.80M
YoY Change	183.3%	-15.01%	809.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$100.7M	$124.9M	$13.20M
YoY Change		846.04%
Other Assets	$33.00K	$9.000K	$15.20M
YoY Change	266.67%	-99.94%	168788.89%
Total Long-Term Assets	$288.0M	$290.9M	$129.6M
YoY Change	124.8%	124.43%	274.49%
TOTAL ASSETS
Total Short-Term Assets	$633.4M	$693.7M	$496.8M
Total Long-Term Assets	$288.0M	$290.9M	$129.6M
Total Assets	$921.5M	$984.6M	$626.4M
YoY Change	48.04%	57.18%	84.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.612M	$6.439M	$3.700M
YoY Change	37.07%	74.03%	-35.26%
Accrued Expenses	$42.41M	$54.00M	$14.78M
YoY Change	172.5%	265.33%	6.78%
Deferred Revenue	$21.48M	$23.55M
YoY Change	1.6%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$81.28M	$91.88M	$54.20M
YoY Change	-5.0%	69.54%	33.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$161.3M	$162.4M	$147.9M
YoY Change	5.86%	9.77%	368.04%
Total Long-Term Liabilities	$161.3M	$162.4M	$147.9M
YoY Change	5.86%	9.77%	368.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.28M	$91.88M	$54.20M
Total Long-Term Liabilities	$161.3M	$162.4M	$147.9M
Total Liabilities	$242.6M	$254.2M	$202.1M
YoY Change	1.94%	25.8%	179.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$769.1M	-$700.5M	-$503.8M
YoY Change	38.09%	39.03%
Common Stock	$96.00K	$95.00K	$87.00K
YoY Change	9.09%	9.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$678.8M	$730.3M	$424.4M
YoY Change
Total Liabilities & Shareholders Equity	$921.5M	$984.6M	$626.4M
YoY Change	48.04%	57.17%	84.14%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$68.62M	-$43.31M	-$58.68M
YoY Change	29.21%	-26.2%	120.54%
Depreciation, Depletion And Amortization	$2.206M	$1.519M	$780.0K
YoY Change	156.51%	94.74%	32.2%
Cash From Operating Activities	-$70.29M	-$33.38M	-$30.74M
YoY Change	240.24%	8.57%	54.94%
INVESTING ACTIVITIES
Capital Expenditures	-$18.37M	-$14.74M	-$950.0K
YoY Change	709.21%	1451.05%	-25.2%
Acquisitions
YoY Change
Other Investing Activities	$89.65M	$92.69M	-$53.19M
YoY Change	-154.75%	-274.27%	-241.65%
Cash From Investing Activities	$71.28M	$77.96M	-$54.14M
YoY Change	-142.93%	-244.0%	-249.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.418M	7.942M	930.0K
YoY Change	-30.39%	753.98%	-99.42%
NET CHANGE
Cash From Operating Activities	-70.29M	-33.38M	-30.74M
Cash From Investing Activities	71.28M	77.96M	-54.14M
Cash From Financing Activities	3.418M	7.942M	930.0K
Net Change In Cash	4.403M	52.53M	-83.95M
YoY Change	-102.42%	-162.57%	-147.13%
FREE CASH FLOW
Cash From Operating Activities	-$70.29M	-$33.38M	-$30.74M
Capital Expenditures	-$18.37M	-$14.74M	-$950.0K
Free Cash Flow	-$51.92M	-$18.64M	-$29.79M
YoY Change	182.35%	-37.43%	60.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36076
	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-1311552
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12278 Scripps Summit Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92131
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	875-1800
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	FATE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95492766
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129180000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167347000
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7311000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5515000
CY2021Q3	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	549521000
CY2020Q4	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	315569000
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7701000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5892000
CY2021Q3	us-gaap	Assets Current AssetsCurrent	693713000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	494323000
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	124877000
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74617000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32308000
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	64970000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	67084000
CY2021Q3	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	11158000
CY2020Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	13506000
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9000
CY2021Q3	us-gaap	Assets Assets	984571000
CY2020Q4	us-gaap	Assets Assets	622457000
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6439000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6283000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54003000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15564000
CY2021Q3	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	3200000
CY2020Q4	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	3200000
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	23545000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21144000
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4697000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3355000
CY2021Q3	fate	Stock Price Appreciation Milestones Liabilities Current StockPriceAppreciationMilestonesLiabilitiesCurrent	0
CY2020Q4	fate	Stock Price Appreciation Milestones Liabilities Current StockPriceAppreciationMilestonesLiabilitiesCurrent	36018000
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	91884000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85564000
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32563000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	46021000
CY2021Q3	fate	Cirm Award Liability Noncurrent CIRMAwardLiabilityNoncurrent	800000
CY2020Q4	fate	Cirm Award Liability Noncurrent CIRMAwardLiabilityNoncurrent	800000
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104360000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93943000
CY2021Q3	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	24632000
CY2020Q4	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	11684000
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95361312
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95361312
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87722237
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87722237
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	95000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	88000
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1430769000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	941216000
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-73000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	70000
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-700462000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556932000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	730332000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	384445000
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	984571000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	622457000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14225000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7558000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38777000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15538000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53130000
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30694000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	146004000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86641000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15718000
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8351000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40385000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23583000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	68848000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	39045000
	us-gaap	Operating Expenses OperatingExpenses	186389000
	us-gaap	Operating Expenses OperatingExpenses	110224000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-54623000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31487000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-147612000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-94686000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	289000
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	447000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1012000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2054000
CY2021Q3	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-11026000
CY2020Q3	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	27644000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-3070000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	27644000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11315000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27197000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4082000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25590000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-43308000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58684000
	us-gaap	Net Income Loss NetIncomeLoss	-143530000
	us-gaap	Net Income Loss NetIncomeLoss	-120276000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-311000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-143000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	290000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3995000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-821000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-43295000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-58995000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-143673000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-119986000
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.49
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95409201
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86887280
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94396485
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80715564
	us-gaap	Profit Loss ProfitLoss	-143530000
	us-gaap	Profit Loss ProfitLoss	-120276000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3644000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2226000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39770000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21992000
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	2708000
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1260000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11057000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	59937000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-3070000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	27644000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1795000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3243000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1921000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12204000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16287000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2626000
	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	2392000
	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	5904000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-92577000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18565000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32335000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2660000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	794712000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	92337000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	431746000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	99950000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-395301000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4953000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17265000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4770000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	411766000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	188784000
	fate	Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreFundedWarrantsNetOfIssuanceCosts	20680000
	fate	Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreFundedWarrantsNetOfIssuanceCosts	0
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	50000000
	fate	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0
	fate	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	33934000
	fate	Proceeds From Cirm Award ProceedsFromCIRMAward	0
	fate	Proceeds From Cirm Award ProceedsFromCIRMAward	440000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	449711000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	277928000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38167000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	264316000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	182574000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100041000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	144407000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364357000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3622000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1183000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1546000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	48099000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129180000
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	349130000
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	144407000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364357000
CY2021Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
CY2020Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-43300000
	us-gaap	Net Income Loss NetIncomeLoss	-143500000
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23900000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23900000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58700000
	us-gaap	Net Income Loss NetIncomeLoss	-120300000
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26100000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26100000
	fate	Period To Treat Award As Grant If Award Not Treated As Loan PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan	P10Y
CY2021Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2021Q3	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2020Q3	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2020Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2021Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2020Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2021Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2020Q3	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2021Q3	us-gaap	Share Price SharePrice	59.27
CY2021Q3	us-gaap	Share Price SharePrice	59.27
	fate	Achievement Of Stock Price Appreciation Milestone AchievementOfStockPriceAppreciationMilestone	-20000000
CY2021Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
	fate	Fair Value Liabilities Level1 To Level3 Transfers Amount FairValueLiabilitiesLevel1ToLevel3TransfersAmount	0
	fate	Fair Value Liabilities Level2 To Level3 Transfers Amount FairValueLiabilitiesLevel2ToLevel3TransfersAmount	0
	fate	Fair Value Liabilities Level3 To Level2 Transfers Amount FairValueLiabilitiesLevel3ToLevel2TransfersAmount	0
	fate	Fair Value Liabilities Level3 To Level1 Transfers Amount FairValueLiabilitiesLevel3ToLevel1TransfersAmount	0
CY2021Q3	fate	Accrued Milestone Payment Under The Amended Msk License Current AccruedMilestonePaymentUnderTheAmendedMskLicenseCurrent	20000000
CY2020Q4	fate	Accrued Milestone Payment Under The Amended Msk License Current AccruedMilestonePaymentUnderTheAmendedMskLicenseCurrent	0
CY2021Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	12200000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4815000
CY2021Q3	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	11005000
CY2020Q4	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	5244000
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10798000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5505000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54003000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15564000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y10M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2021Q3	fate	Straight Line Lease Expense StraightLineLeaseExpense	3538000
CY2020Q3	fate	Straight Line Lease Expense StraightLineLeaseExpense	3039000
	fate	Straight Line Lease Expense StraightLineLeaseExpense	10617000
	fate	Straight Line Lease Expense StraightLineLeaseExpense	8948000
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	529000
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	608000
	us-gaap	Variable Lease Cost VariableLeaseCost	1120000
	us-gaap	Variable Lease Cost VariableLeaseCost	1633000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	4067000
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3647000
	us-gaap	Operating Lease Cost OperatingLeaseCost	11737000
	us-gaap	Operating Lease Cost OperatingLeaseCost	10581000
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	400000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3662000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13313000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12988000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13378000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13779000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	14193000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	116254000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	187567000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	78510000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	109057000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13540000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7843000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39770000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21992000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	384445000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5648000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12976000
CY2021Q1	fate	Public Offering Of Common Stock And Issuance Of Pre Funded Warrants PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432445000
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-330000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-45089000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	790095000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3681000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	219218000
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2548000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7236000
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188791000
CY2020Q2	fate	Common Stock Issued During Period Value Private Placement1 CommonStockIssuedDuringPeriodValuePrivatePlacement1	49975000
CY2020Q2	fate	Stock Issued During Period Value Collaboration Partner StockIssuedDuringPeriodValueCollaborationPartner	33934000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13254000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	174000
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	481000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-28072000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	474111000
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1413000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7843000
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-7000
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-311000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58684000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	424365000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55133000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	752071000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8016000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13540000
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-43308000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	730332000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	244756000
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	949000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6913000
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	120000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-33520000

Files In Submission

Name	View Source	Status
0000950170-21-003066-index-headers.html	Edgar Link	pending
0000950170-21-003066-index.html	Edgar Link	pending
0000950170-21-003066.txt	Edgar Link	pending
0000950170-21-003066-xbrl.zip	Edgar Link	pending
fate-20210930.htm	Edgar Link	pending
fate-20210930.xsd	Edgar Link	pending
fate-20210930_cal.xml	Edgar Link	unprocessable
fate-20210930_def.xml	Edgar Link	unprocessable
fate-20210930_htm.xml	Edgar Link	completed
fate-20210930_lab.xml	Edgar Link	unprocessable
fate-20210930_pre.xml	Edgar Link	unprocessable
fate-ex31_1.htm	Edgar Link	pending
fate-ex31_2.htm	Edgar Link	pending
fate-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
Fate Therapeutics Inc Stock $fate

2021 Q4 Form 10-Q Financial Statement

#000095017021003066 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE Fate Therapeutics Inc Stock $fate

2021 Q4 Form 10-Q Financial Statement

#000095017021003066 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
Fate Therapeutics Inc Stock $fate